GlassScriptPhysician profile
Su Yun Chung
NPI 1538523642
$515.44
in general payments reported to CMS, 2019-2025
13 companies · $123 in 2025
The $123 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $73.99 · 2023: $81.45 · 2024: $237 · 2025: $123.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $441.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $441.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $88.14 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $73.99 | 2022 | |
| Menarini Silicon Biosystems, INC. | $53.88 | 2023-2024 | Cellsearch |
| Alexion Pharmaceuticals, INC. | $49.84 | 2024 | Ultomiris |
| Tempus Ai, INC | $45.10 | 2025 | Xt Cdx |
| Abbvie INC. | $39.51 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $31.28 | 2024 | Keytruda |
| Agios Pharmaceuticals, INC. | $29.85 | 2025 | Pyrukynd |
| G1 Therapeutics, INC. | $24.66 | 2023 | Cosela |
| Eisai INC. | $23.25 | 2024 | |
| Janssen Biotech, INC. | $21.57 | 2024 | Tecvayli, Talvey, Darzalex |
| Pharmacyclics LLC, An Abbvie Company | $18.49 | 2023 | Epkinly |
| Foundation Medicine, INC. | $15.88 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Su Yun Chung listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.